TLDR:
- Antheia, a pharmaceutical ingredient manufacturer based in Menlo Park, CA, raised $17M in funding.
- The funding included a non-dilutive two-year project agreement up to $11M through the BioMaP Consortium.
Antheia, led by CEO Christina Smolke, is focused on producing critical pharmaceutical ingredients using a novel whole-cell engineering approach. The company’s biomanufacturing platform allows for the reconstruction of biosynthetic pathways in yeast cells and the scaling of fermentation processes to commercial levels. This enables on-demand production of pharmaceutical ingredients, supporting modern healthcare needs.
The funding from In-Q-Tel, Inc. (IQT), Echo Investment Capital (Echo), and existing investors like Viking Global Investors, will be used to accelerate Antheia’s commercialization strategy and increase production of pharmaceutical ingredients to the U.S. market.
Full Article:
Antheia, a pharmaceutical ingredient manufacturer based in Menlo Park, CA, recently secured $17M in funding. The funding round included a $11M non-dilutive two-year project agreement through the BioMaP Consortium, as well as investments from In-Q-Tel, Inc. (IQT), Echo Investment Capital (Echo), and existing investors like Viking Global Investors.
Led by CEO Christina Smolke, Antheia specializes in producing critical pharmaceutical ingredients using a unique whole-cell engineering approach. Their biomanufacturing platform allows for the reconstruction of biosynthetic pathways in yeast cells and the scalable production of fermentation processes to commercial levels. This innovative approach enables agile and resilient production of pharmaceutical ingredients, addressing the needs of modern healthcare systems.
The funds raised by Antheia will be used to accelerate the company’s commercialization strategy and ramp up production of pharmaceutical ingredients for the U.S. market. This investment will support Antheia’s mission to provide on-demand production of vital pharmaceutical components.
